AVCT Share Price Performance
UK£0.65
0.17 (35.42%)
20.0% undervalued intrinsic discount
UK£0.81
Fair Value
Price UK£0.65
AnalystConsensusTarget UK£0.81
Fair ValueUK£0.81
Share Pricen/a
Avacta Group Plc Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
AVCT Community Narratives
AN
Fair Value UK£0.81 20.0% undervalued intrinsic discount
Oncology Pipeline Progress And FAP Targeting Are Expected To Drive Long Term Upside
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Oncology Pipeline Progress And FAP Targeting Are Expected To Drive Long Term Upside
Catalysts About Avacta Group Avacta Group is a clinical stage oncology company developing tumor targeted chemotherapies using its proprietary pre|CISION drug delivery platform. What are the underlying business or industry changes driving this perspective?Read more
10
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
UK£0.81
20.0% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
-5.46% p.a.
Profit Margin
31.68%
Future PE
11.93kx
Price in 2028
UK£1
Trending Discussion
Recently Updated Narratives
AN
Oncology Pipeline Progress And FAP Targeting Are Expected To Drive Long Term Upside
Fair Value: UK£0.81 20.0% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Avacta Group Plc Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -0.094
- 100.00%
- -35,897.35%
- 12,804.2%
About AVCT
- Founded
- 2003
- Employees
- 151
- CEO
- WebsiteView website
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that drives localization to fibroblast activation protein expressing tumors. The company was incorporated in 2003 and is headquartered in London, the United Kingdom.
